Boston Scientific Corp. Hits New 52-Week Low at $42.25

Boston Scientific Corp. has reached a significant milestone by touching a new 52-week low of USD 42.25 on June 30, 2026. This decline reflects a challenging year for the company, with its stock price down approximately 44.87% over the past year, contrasting sharply with the S&P 500's performance of 20.86% during the same period. As a large-cap player in the retailing industry, Boston Scientific Corp. holds a market capitalization of USD 120,852 million. The company's price-to-earnings (P/E) ratio stands at 36.00, indicating how the market values its earnings relative to its stock price. Additionally, the company has a debt-to-equity ratio of 0.39, suggesting a relatively low level of debt compared to its equity. The return on equity is reported at 13.88%, reflecting the company's ability to generate profit from its shareholders' equity. Despite the current stock price challenges, Boston Scientific Corp. continues to maintain a price-to-book ratio of 4.99, which provides insight into its valuation relative to its assets. The absence of a dividend yield indicates that the company is likely reinvesting its earnings back into the business.